Cellectar Biosciences has expanded its licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin…
Cellectar Biosciences is partnering with Florida Cancer Specialists & Research Institute (FCS) to advance patient care and further define the U.S. treatment landscape, the company announced today. According to a…
Cellectar Biosciences has closed its $103 million private placement financing, the company announced today. According to a release, the financing was led by Rosalind Advisors with participation from AIGH Capital,…
Cellectar Biosciences has been awarded $1.98 million in additional grant funding by the National Institute of Health’s National Cancer Institute (NCI), the company announced today. According to a release, the…
Cellectar Biosciences has been awarded a $2 million Phase II National Institutes of Health (NIH) SBIR grant from the National Cancer Institute (NCI), the company announced recently. According to a…
Cellectar Biosciences and LegoChemBio, a clinical-stage biotechnology company in South Korea, have entered a development and commercialization collaboration, the company announced today. According to a release, the two companies have…
Cellectar Biosciences has received another patent by the Japanese Patent Office, this time for its proprietary phospholipid-ether (PLE), the company announced today. According to a release, the patent provides composition…
The European Commission has granted Cellectar Biosciences orphan drug designation and 10 years of European market exclusivity for CLR 131 in Waldenstrom’s Macroglobulinemia (WM), the company announced today. “Receipt of European orphan…
Cellectar Biosciences has started a trial for CLR 131 in Waldenstrom’s macroglobulinemia (WM), the company announced recently. According to a release, the trial will include 50 WM patients who will…
Cellectar Biosciences announced today the pricing of its underwritten public offering of its common stock at $1.35 per share, which will result in gross proceeds of approximately $24.5 million. Cellectar also…
